Alfred Dadson

Al serves as the Chief Manufacturing Officer, Global Biologics Operations and is responsible for process development and manufacturing of our antibodies, vaccine and Cell Therapy manufacturing through commercialization. Al is an industry veteran with 38 years of broad expertise in process development, process engineering, manufacturing from early stage to commercial and facilities engineering. Before assuming this role, Al was Vice President of Antibody Manufacturing Operations and Site Head of Agenus West. Under his leadership, a record number of 8 antibody programs have been developed and manufactured through successful IND acceptance in less than 2 years. Prior to joining Agenus, Al spent 15 years at XOMA as Vice President, Manufacturing Operations and Facilities Engineering and holds a patent on state-of-the-art modular facility design. He was part of senior management where his team worked on over 20 antibody programs into the clinic. Among his key achievements at XOMA was the successful development of XOMA/Servier Gevokizumab antibody to CMC BLA readiness in 2 years. While at XOMA, Al led several successful CMC collaborations with companies like Chiron, Novartis, Pfizer, Aveo Pharmaceuticals, Alexion, Department of Defense and Servier to name a few for antibody process development and manufacturing by XOMA. Prior to joining XOMA, Al spent 20 years at Bayer Healthcare site in Berkeley as Senior Principal Scientist and was responsible for all upstream clinical process development and manufacturing programs. He led the CMC team at Bayer for the development and commercialization of Bayer’s first biotechnology drug Kogante®. Al is a lifetime member of Who is Who in Industry leaders selected by his peers.